sglt2 with glp 1 Cardiorenal Protection: Potential of Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes | Diabetes Therapy SGLTi and GLP-1 in HF

Results In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database

Cognition improved in exenatide treated patients in fluid intelligence (baseline 38.4 (8.2), 12 weeks 52.9 (6.6), p=0.0005), processing speed (baseline 43.7 (9.4), 12 weeks 58.4 (10.4), p=0.0058) and episodic memory (baseline 49.4 (5.3), 12 weeks 62.1 (13.2), p=0.0315)

Prime Labs does not condone or support the use of peptides outside of controlled scientific research

95% CI 0.750.98, p=0.03), Dulaglutide (RR 0.82, 95% CI 0.700.96, p=0.02), Albiglutide (RR 0.93,95% CI 0.791.10, p=0.40), Exenatide (RR 0.93, 95% CI 0.741.18, p=0.55), Lixisenatide (RR 0.83, 95% CI 0.621.12, p=0.22), and Efpeglenatide (RR 0.76, 95% CI 0.461.24, p=0.27)